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Background: The expression of μ-opioid receptor has important role in cognitive dysfunction in Schizophrenia (SZ).
The results of studies about the association of polymorphisms of μ-opioid receptor gene (OPRM1) with SZ were
inconsistent.
Methods: We conducted a case–control study to investigate the genetic association between OPRM1
polymorphisms and SZ among the Han chinese population. 264 SZ patients and 264 age-matched control subjects
were recruited. Four SNPs of OPRM1 were successfully genotyped by using PCR-RFLP.
Results: Of four polymorphisms, rs1799971 and rs2075572 were shown to associate with SZ. Compared with the A
allele of rs1799971 and C allele of rs2075572, the G allele of rs1799971 and rs2075572 was associated with an
almost 0.46-fold risk (OR = 0.46, 95% CI: 0.357-0.59, P < 0.01) and 0.7-fold risk (OR = 0.707, 95% CI: 0.534-0.937,
P = 0.015) of the occurrence of SZ,. When subjects were divided by gender, rs1799971 remained significant
difference only in males (OR = 0.309, 95% CI: 0.218-0.439 for G allele, P < 0.01), and rs2075572 only in females
(OR = 0.399, 95% CI: 0.246-0.648 for G allele, P < 0.01). In secondary analysis with subsets of patients, the G allele of
rs1799971 (compared to the A allele) was associated with a decreased risk of all patients and male patients with
apathy symptoms (OR = 0.086, 95% CI: 0.048-0.151, P = 0.01; OR = 0.083, 95% CI: 0.045-0.153, P < 0.01), and the G
allele of rs2075572 (compared to the C allele) was associated with a decreased risk of all patients and female
patients with positive family history (OR = 0.468, 95% CI: 0.309-0.71, P < 0.01; OR = 0.34, 95% CI: 0.195-0.593, P < 0.01).
In addition, haplotype analysis revealed that two SNP haplotypes (A-C-C-G and G-C-C-A) were associated with
decreased risks of SZ (P < 0.01). The other two (G-C-C-G and G-G-C-G) with increased risks of SZ (P < 0.01).
Conclusions: The present study demonstrated for the first time that the OPRM1 polymorphism may be a risk factor
for schizophrenia in the Han Chinese. Further studies are needed to give a global view of this polymorphism in
pathogenesis of schizophrenia in a large-scale sample, family-based association design or well-defined subgroups of
schizophrenia.
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Schizophrenia (SZ) is a common, chronic and complex
psychiatric disorder, affecting 1.0% of the worldwide
population [1]. The disorder presents delusions and hal-
lucinations, reduced interest and drive, altered emotional
reactivity and disorganized behavior [2]. The data col-
lected from family, twin, and adoption studies show un-
equivocally that SZ is a predominantly genetic disorder,
and heritability estimates for SZ range from 70% to 80%* Correspondence: firstdsdan@hotmail.com
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reproduction in any medium, provided the or[3]. Traditionally, Genetic research of SZ focused on
identifying linkage regions or on candidate genes and
polymorphisms. Now a few studies have obtained posi-
tive replications, including chromosomal locus and sus-
ceptibility genes [4,5]. Apparently, however, effect sizes
are small and individual studies were not replicated by
other groups. Recently, genome-wide association studies
(GWAS) provided new evidence for SZ genetics, by in-
vestigating single nucleotide polymorphism (SNP) and copy
number variation [6-9]. Some results suggest that multiple
functional variants from genes in neurodevelopmentald. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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biological mechanism is undefined.
Theμ-opioid receptor (MOR; encoded by genetic locus
OPRM1) is widely distributed in the brain, and is highly
expressed in the thalamus, caudate putamen and globus
pallidus [10]. MOR has a high affinity for b-endorphin
and enkephalin but a low affinity for dynorphin (which
preferentially binds to the k-opioid receptor), and it also
binds to exogenous opioid drugs (e.g. morphine, heroin
and methadone) with a high affinity. MORs are thought
to be responsible for most opioidergic actions such as
euphoria, analgesia and opiate drug withdrawal [11].
Disruption of the MOR gene (Oprm) in mice abolishes
morphine-induced analgesia, place-preference activity
and physical-dependence, even in the presence of intact
d- and k-opioid receptors (DOR and KOR) [12,13]. More
than 250 SNPs have been identified in the OPRM1 gene
[14-16]. The A118G SNP in exon1 leads to an amino acid
substitution that changes the putative N-glycosylation site
[17]. A118G (rs1799971) has been studied in relation to
tardive dyskinesia in selected groups of patients in Japan
and China [18,19]. This polymorphism, leading to a substi-
tution of asparagine (Asn) for aspartic acid (Asp) at amino
acid position 40, reduces through changed receptor glyco-
sylation the affinity for endogenous opioids [20].
In addition, intronic sequence can be involved in alter-
native DNA splicing. To date, nine human OPRM1
splice variants have been identified [21-23]. They contain
the same exons 1, 2 and 3 as the original human
OPRM1,which normally has four exons. However, they
differ from this sequence and from each other by spli-
cing downstream from exon3. All splice variants result
in amino acid sequence changes in the C-terminus of
the MOR and may affect the activity (e.g. phosphory-
lation and internalization) of the receptor. rs2075572 (C/G)
is in intron2; rs648893 (C/T) is in intron3; rs671531 (A/G)
is in the downstream region of the OPRM1 gene.
SZ has been linked to dysfunction of prefrontal cor-
tical (PFC) g-aminobutyric acid (GABA) neurons and
appears neurodevelopmental in nature [24-28]. OpioidsFigure 1 The human μ-opioid receptor gene (OPRM1) structure and 4suppress GABA neuron activity [29], so higher MOR
mRNA levels existing in SZ may contribute to suppressed
PFC GABA neuron activity [30-32]. The rs1799971 poly-
morphism of the OPRM1 gene has an impact on μ-opioid
receptors functioning [18,33]. So the G allele rs1799971
leads to decreased expression of the receptor [34].
There is also a possible relationship between dys-
function of this receptor and opiates abuse in SZ pa-
tients [35].
Therefore, we designed an association study aimed at
OPRM1 gene polymorphism in relation to SZ-——a
case–control study to investigate the association of al-
leles, genotypes, haplotypes of 4 SNPs (rs1799971,
118A/G or Asn40Asp; rs2075572, C/G; rs648893, C/T;
rs671531, A/G) of OPRM1 (Figure 1) with SZ in a group
of the Han Chinese population.
Methods
Subjects characteristics
The studied sample consisted of 264 patients with SZ
(154 males and 110 females; mean age: 37.44 ± 11.04 -
years old) and 264 healthy controls (146 males and 118
females; mean age: 36.38 ± 12.27 years old). All patients
were recruited from inpatient or outpatient in the Fifth
People’s Hospital of Ruian city. These patients were unre-
lated Han Chinese born and living in southern Zhejiang
province, and all their biological grandparents were of Han
Chinese ancestry. The consensus diagnoses were made by
at least two experienced psychiatrists according to the Diag-
nostic and Statistical Manual of Mental Disorders-Fourth
Edition IV (DSM-IV) (1994) diagnostic criteria for paranoid
SZ. Individuals with a history of severe medical complica-
tions, such as diabetes, cardiovascular disease, hypertension,
neurological diseases, any concomitant major psychiatric
disorders, or substance dependence were excluded.
Healthy controls were recruited from hospital staffs
who had volunteered to paticipate.
The Mini-International Neuropsychiatric Interview
was performed in the control group [36] followed by an
interview with a psychiatrist. All individuals with mentalSNP variants.
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were excluded from the control group. All participants
signed informed consent forms to join the study partici-
pation, and these forms remain stored.
Those individuals with personal or family history of
neurological diseases and mental health, such as diagno-
ses of major depressive disorder, SZ or bipolar mood dis-
order were excluded. The controls living in the same
area as patients were well matched to patient group on
gender, age (F = 0.699, p = 0.403) and ethnicity.
The approval of Clinical research professional commit-
tee of the First Affiliated Hospital of Wenzhou Medical
College was obtained, and all subjects, both cases and
controls, gave written informed consent to participate.Selection of subsets
The psychiatric symptoms of the patients were rated
using the Brief Psychiatric Rating Scale (BPRS) [37,38].
The principal component analyses of the symptoms
assessed by the BPRS were also performed, and five fac-
tors emerged: Delusion of reference, genuine auditory
hallucination, delusion of persecution, bizarre behavior,
and apathy delusion [39]. The patients were classified
into five subgroups according to clinical symptoms. All
patients have more than one symptom.
The second subset was composed of patients stratified
by age-of-onset, divided into two subgroups (age 18 or
less and more than 18; 18 years and >18 year). Referring
to our previous studies, the age at onset of schizophrenia
was defined as the age when positive symptoms (either
delusions or hallucinations) first became apparent based
on interviews and supplemental clinical information
obtained from medical records and family informants
[40,41]. Onset before 19 years of age is known as early
age-of-onset [42]. The third subset was composed of pa-
tients stratified by family history, divided into two sub-
groups (positive and negative family history). The
definition of positive family history of SZ was verified
presence of one or more, 1st or 2nd degree relatives










Blood samples were collected with the anticoagulant
EDTA K2 and stored at −20°C. Genomic DNA was
extracted from the blood using a DNA Extraction Kit
(TaKaRa Bio Group, Japan). OPRM1 polymorphisms
were genotyped by PCR-RFLP and the condition was
displayed in the Table 1. We selected the four single nu-
cleotide polymorphisms (SNPs) in the OPRM1 gene
according to the dbSNP http://www.ncbi.nlm.nih.gov/
SNP/ and the international HapMap project http://www.
hapmap.org/, including rs1799971, rs2075572, rs648893,
rs671531.
These markers cover 80045 bp of the OPRM1 coding
region (Figure 1).
The four SNPs were analyzed by polymerase chain
reaction-restriction fragment length polymorphism (PCR-
RFLP) analysis. The information of primers and PCR-
RFLP analysis is given in Table 1. The PCR amplification
was performed in a 50 μl volume containing GC Buffer
(TaKaRa), 200 mM of each dNTPs, 0.3 mM of each pri-
mer, 1 U of Taq DNA polymerase, and 40 ng of the gen-
omic DNA. The conditions used for PCR amplification
were an initial denaturation phase at 94°C for 5 min,
followed by 36 cycles at 94°C for 30 sec, annealing at 50-
65°C for 30–60 sec, and extension at 72°C for 30 sec,
followed by a final extension phase at 72°C for 7 min. A
10 μL aliquot of the PCR product mixtures was com-
pletely digested with 1–3 units of restriction enzyme in 2–
4 hours at 37°C. Digestion products were visualized
through ethidium bromide staining after electrophoresis
in 1%-3% agarose gels.
Power calculations
Power calculations were performed using the Genetic
Power Calculator [44]. We assumed that the polymor-
phism and the disease locus were in complete linkage dis-
equilibrium (LD) and that they had the same allele
frequencies, ie, the polymorphism was the disease locus.
Assuming a recessive disease locus and a disease prevalence
of 0.02. Our exploratory sample size of 264 cases and 264





Table 2 Distribution of OPRM1 genotypes and alleles between SZ cases and controls in all, female and male samples*
SNP Haplotype/Allele All Male Female
Controls Cases OR (95%) P value Controls Cases OR (95%) P value Controls Cases OR (95%) P value
rs799971 AA 68 132 1.00(referent) 31 93 1.00(referent) 37 39 1.00(referent)
AG 133 102 0.417(0.281-0.618) <0.00001 85 50 0.208(0.121-0.358) <0.00001 48 52 1.063(0.582-1.941) 0.84
GG 63 30 0.257(0.152-0.436) <0.00001 30 11 0.127(0.057-0286) <0.0.00001 33 19 0.564(0.273-1.164) 0.12
A 269 366 1.00(referent) 147 236 1.00(referent) 122 130 1.00(referent)
G 259 162 0.46(0.357-0.59) <0.00001 145 72 0.309(0.218-0.439) <0.00001 114 90 0.741(0.511-1.073) 0.11
HWE(P) 0.9 0.14 0.4 1.00 0.37 0.68
rs2075572 CC 140 166 1.00(referent) 79 84 1.00(referent) 61 82 1.00(referent)
CG 100 82 0.697(0.481-1.010) 0.06 51 55 1.053(0.643-1.725) 0.84 49 27 0.383(0.213-0.689) 0
GG 24 16 0.594(0.301-1.171) 0.59 16 15 0.951(0.437-2.071) 0.9 8 1 0.087(0.01-0.723) 0.02
C 380 414 1.00(referent) 209 223 1.00(referent) 171 191 1.00(referent)
G 148 114 0.707(0.534-0.937) 0.02 83 85 0.96(0.672-1.371) 0.82 65 29 0.399(0.246-0.648) <0.00001
HWE(P) 0.32 0.68 0.96 0.91 0.56 0.68
rs648893 CC 107 116 1.00(referent) 55 69 1.00(referent) 52 47 1.00(referent)
CT 113 110 0.888(0.61-1.292) 0.54 59 57 0.755(0.453-1.259) 0.28 54 53 1.102(0.631-1.925) 0.73
TT 44 38 0.76(0.455-1.268) 0.29 32 28 0.671(0.36-1.253) 0.21 12 10 0.848(0.331-2.171) 0.73
C 327 342 1.00(referent) 169 195 1.00(referent) 158 147 1.00(referent)
T 201 186 0.885(0.689-1.137) 0.34 123 113 0.796(0.573-1.105) 78 73 1.006(0.681-1.486) 0.98
HWE(P) 0.13 0.06 0.96 0.84 0.38 0.21
rs671531 AA 102 109 1.00(referent) 56 68 1.00(referent) 46 41 1.00(referent)
AG 116 122 0.968(0.665-1.408) 0.87 63 69 0.893(0.544-1.465) 0.65 53 53 1.091(0.613-1.942) 0.77
GG 46 33 0.628(0.37-1.065) 0.09 27 17 0.482(0.237-0.981) 0.04 19 16 0.902(0.406-2.004) 0.8
A 320 340 1.00(referent) 175 205 1.00(referent) 145 135 1.00(referent)
G 208 188 0.851(0.663-1.092) 0.2 117 103 0.752(0.539-1.048) 0.09 91 85 1.003(0.688-1.463) 0.99
HWE(P) 0.2 0.08 0.95 1.00 0.67 1.00
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with minor allele frequencies ≥ 0.2. A dominant model had
80% power to detect a locus with a genotypic relative risk ≥
1.7 and a SNP minor allele frequency ≥ 0.1 atα ≤ 0.1.Statistical analysis
Genotype and allele frequencies were compared between
patients and controls using the SHEsis software [45].
HWE was also tested using this program. The standard-
ized measure of linkage disequilibrium (LD) coefficients
(D’), haplotype frequency, haplotype block, and haplo-
type association were also assessed using the SHEsis
software. Single-SNP analysis was carried out using the
Pearson chi-square test on allele and genotype counts.
Unconditional logistic regression analysis models were
used to evaluate the relationships between different ge-
notypes and disease risk [Odds ratios (OR), 95% confi-
dence intervals (95% CI)] adjusted by age, a p-value of
less than 0.05 was considered as statistically significant.
Correction for multiple testing of SNPs that are in LD
with each other was applied according to the method in-
troduced by Li & Ji [46] which improves an approach
proposed by Nyholt [47], and consequently single-test p-
values < 0.01 were considered to be significant.Results
Comparison of the allelic and genotypic frequencies of
SNPs in patient and control group
Four OPRM1 SNPs were detected in 528 ethnic Chinese
schizophrenic patients. These were rs1799971 (118A/G
or Asn40Asp), rs2075572 (C/G), rs648893 (C/T) and
rs671531 (A/G). Among the four SNPs, only rs1799971
was in coding region, causing an amino acid substitution
(Asn40 to Asp40) that removes a highly conserved N-
glycosylation site in the extracellular domain of the pro-
tein. A significant deviation from the Hardy-Weinberg
equilibrium was not found in either the patient group or
in the control group for all four SNPs. Genotypic and al-
lelic frequencies of four SNPs are shown in Table 2. Stat-
istical analysis revealed a significant difference for the
rs1799971, rs2075572 polymorphisms, while other poly-
morphisms did not show any significant differences.
A significant difference in both genotype and allele at
rs1799971 was found between SZ patients and controls.
Compared with rs1799971 AA, subjects with AG and
GG genotypes were associated with a decreased risk
(OR = 0.417, 95% CI: 0.281-0.618, P < 0.00001; OR =
0.257, 95% CI: 0.152-0.436, P < 0.00001). The frequency
of the A allele of rs1799971 were also lower in patients
(50.9%) than in controls (69.3%, OR = 0.46, 95% CI:
0.357-0.591, P < 0.00001). There was a significant differ-
ence in allelic frequencies at rs2075572. Compared with
rs2075572 C allele, subjects with G allele were associatedwith a decreased risk (OR = 0.707, 95% CI: 0.534-0.937,
P = 0.015).
To determine the gender effect, genotype and allele fre-
quency in both sexes were assessed (Table 3). In male
samples, rs1799971 showed significant difference be-
tween SZ patients and controls in the genotype and al-
lele. Compared with AA, subjects with AG and GG
genotypes were associated with a decreased risk (OR =
0.208, 95% CI: 0.121-0.358, P < 0.00001; OR = 0.127, 95%
CI: 0.057-0.286, P < 0.00001). Compared with A allele,
subjects with G allele were associated with a decreased
risk (OR = 0.309, 95% CI: 0.218-0.439, P < 0.00001). In fe-
male samples, there was a significant difference in both
genotypic and allelic frequencies at rs2075572 between
SZ patients and controls. Compared with CC genotype,
subjects with CG and GG genotypes were associated with
a decreased risk (OR = 0.383, 95% CI: 0.213-0.689, P =
0.001; OR = 0.087, 95% CI: 0.01-0.723, P = 0.024). Com-
pared with C allele, subjects with G variant allele were
associated with a decreased risk (OR = 0.399, 95% CI:
0.246-0.648, P < 0.00001).
Secondary analysis with assumedly genetic subsets of
patients
When stratifying patients according to five main clini-
cal symptoms (delusion of reference, genuine auditory
hallucination, delusion of persecution, bizarre behavior,
and apathy), the genotypic and allelic frequencies at
rs1799971 and rs2075572 sites were compared between
every subgroup and the original control group (Table 3).
Only in the subgroup(s) with apathy symptoms, the fre-
quency of the G allele of rs2075572 was 15.42% SZ with
apathy symptoms, significantly lower than that in con-
trols (28.03%). The G allele of rs2075572 (compared to
the A allele) was associated with a decreased risk of all
patients and female patients with apathy symptoms
(OR = 0.468, 95% CI: 0.309-0.71, P < 0.00001; OR = 0.34,
95% CI: 0.195-0.593, P < 0.00001).
When stratifying patients by age-of-onset, the geno-
typic and allelic frequencies of rs1799971 and rs2075572
in two subgroups were compared with that of the ori-
ginal control group. However, there was no significant
association of the minor allele of the two SNP with a
risk of SZ with early age-of-onset (age 18 or less).
When stratifying patients by family history, the G al-
lele of rs1799971 in all and male patients with positive
family history (7.61%, 7.56%) was lower frequently than
that of controls (49.05%; 49.66%), and the OR values
were 0.086 and 0.083, respectively (95% CI: 0.048-0.151,
P =0.01; 95% CI: 0.045-0.153, P < 0.00001). While the
OR value for the G allele of rs2075572 was 0.499 and
0.347 (versus the C allele) among all and female patients
of negative family history (95% CI: 0.354-0.704, P <
0.00001; 95% CI: 0.203-0.595, P < 0.00001).
Table 3 Comparison of the genotypic and allelic frequencies of rs1799971 and rs2075572 in different kinds of patients compared with controls by BsmI
polymorphisms*
SNP Gender Haplotype Controls Clinical symptoms
Delusion
of reference
OR(95% CI) Genuine auditory
hallucination




OR(95% CI) Apathy OR(95% CI)
rs799971 All AA 68 53 1.00(referent) 40 1.00(referent) 34 1.00(referent) 51 1.00(referent) 30 1.00(referent)




















A 269 198 1.00(referent) 158 1.00(referent) 137 1.00(referent) 203 1.00(referent) 117 1.00(referent)










Male AA 31 26 1.00(referent) 24 1.00(referent) 16 1.00(referent) 21 1.00(referent) 15 1.00(referent)




















A 147 97 1.00(referent) 96 1.00(refrent) 64 1.00(referent) 86 1.00(referent) 76 1.00(referent)










rs2075572 All CC 140 91 1.00(referent) 83 1.00(referent) 68 1.00(referent) 90 1.00(referent) 76 1.00(referent)




















C 380 251 1.00(referent) 215 1.00(referent) 179 1.00(referent) 258 1.00(referent) 181 1.00(referent)










Female CC 61 35 1.00(referent) 45 1.00(referent) 31 1.00(referent) 25 1.00(referent) 64 1.00(referent)
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C 171 90 1.00(referent) 117 1.00(referent) 86 1.00(referent) 77 1.00(referent) 147 1.00(referent)
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The results of LD between each pair of SNPs are shown
in Table 4. The LD analysis revealed that three SNPs
(rs2075572, rs648893 and rs671531) were in an LD block
(|D’| > 0.9) (Figure 2), which is consistent with other
studies [48]. The rs2075572 showed significant LD with
rs648893 and rs671531. In addition, there was strong LD
between rs648893 and rs671531.
The distributions of haplotypes of the four SNPs are
listed in Table 5. Haplotypes with four loci (rs1799971,
rs2075572, rs648893 and rs671531) of OPRM1 gene
polymorphisms were analyzed. We found that the fre-
quencies of haplotypes ‘A-C-C-G and G-C-C-A’ were
2.7% and 4.4% of cases, significantly lower than in con-
trols (15.6% and 10.6%), and the odds ratios were 0.149
(95% CI: 0.084–0.266, P < 0.00001) and 0.386 (95% CI:
0.233–0.638, P < 0.00001) respectively, while the haplo-
type ‘G-C-C-G and G-G-C-G’ was more frequent in
cases than in controls (13% vs. 3.4% and 13.7% vs.
5.1%, P < 0.00001), while the odds ratio values were
4.317 (95% CI: 2.526–7.377, P<0.00001) and 2.984 (95% CI:
1.881–4.732, P<0.00001).
Discussion
The m-opioid receptor MOR; encoded by genetic locus
OPRM1) is widely distributed in the brain, and is highly
expressed in the thalamus, caudate putamen and globus
pallidus [10,11]. MORs are thought to be responsible for
most opioidergic actions such as euphoria, analgesia and
opiate drug withdrawal [11]. MOR binds to exogenous
opioid drugs (e.g. morphine, heroin and methadone)
with a high affinity. Clinical effects of some opioid ago-
nists (morphine, methadone) are accompanied by modula-
tion of the dopaminergic, glutamatergic, and GABAergic
transmission in the human brain. The evidence of an indir-
ect effect includes increased dopamine release in indi-
viduals with SZ [49,50]. Therefore, the mutation of
OPRM1gene, leading to the inactivation of MOR and re-
duced dopamine release, has no susceptibility to SZ.
This study has brought out a finding of an association of
the μ-opioid receptor gene (OPRM1gene) polymorphism
with SZ again by more SNPs (rs1799971, rs2075572,
rs648893 and rs671531). A currently published article hasTable 4 Linkage disequilibrium test between four OPRM1
gene polymorphisms
SNP1 SNP2 Physical distance(bp) r2
rs1799971 rs2075572 51207 0.02
rs1799971 rs648893 77832 0
rs1799971 rs671531 79945 0.02
rs2075572 rs648893 26625 0.18
rs2075572 rs671531 28738 0.3
rs648893 rs671531 2113 0.32shown that morphine, which acts as a μ- opioid agonist,
increases prepulse inhibition of startle reaction that is sig-
nificantly deficient in patients with SZ.
P < 0.00001 A group of Czech authors found that the
rs1799971 polymorphism of the OPRM1 gene was asso-
ciated with increased risk of SZ in the male population
[51]. However, our results show that the probability of
having SZ for those with the G variant of rs1799971 and
rs2075572 was decreased, compared to people carrying
the A-allele and C-allele, suggesting that the “G” allele of
rs1799971 and rs207557 might have a protective effect
against SZ. A group of Japanese authors tried to docu-
ment the association between the rs1799971 polymor-
phism of the OPRM1 gene and tardive dyskinesia in SZ
patients. They documented that the G allele was signifi-
cantly less represented in patients with tardive dyskinesia,
which presented its “protective” role [18]. A following
Chinese study observed a similar trend of the G allele be-
ing less frequent in subjects with tardive dyskinesia in SZ
patients [33].
The level of MOR mRNA in SZ was elevated, having
important role in cognitive dysfunction [32]. And the G
allele of rs1799971 has impact on μ-opioid receptors
functioning, leads to decreased expression of the recep-
tor [18,33,34]. Therefore, our results were consistent
with the role of μ-opioid receptors in SZ.
In our study a lower frequency of the G allele and the
GG genotype in rs1799971 and rs2075572 was found in
patients with SZ. The results allow a hypothesis that a
possible increased expression of the μ-opioid receptor in
individuals with SZ, caused by the absence of the G al-
lele, and may thus lead to the hyperactivity in the dopa-
mine system. There are several possible explanations for
the above discrepancies between the previous reports
and our results. The first possibility relates to the differ-
ent ethnicities of the subjects. Some inconsistent results
in association studies may be attributed to genetic het-
erogeneity since the various studies were carried out in
distinct ethnic populations. The second possibility re-
lates to the gender effect. When our subjects were di-
vided by gender, one SNPs (rs2075572) was associated
with SZ in females, but another SNPs (rs1799971) was
associated with SZ in males.
Many studies have demonstrated that there is a gender
difference in clinical factors of SZ such as symptomatol-
ogy, premorbid functioning and age of onset [52]. The
gender effect on SZ at genetic level was also repor-
ted [53,54].
It is well known that the incidence of complicated dis-
eases like SZ depend on the interaction of multiple fac-
tors. Usually no single gene is uniquely responsible for
these diseases and environmental factors also play a role
in their occurrence. The methods used in individual
studies, may have limited power to detect a small effect,
Figure 2 Linkage disequilibrium (LD) plot of 4 OPRM1 SNPs in SZ cases and controls. There was only one LD block in OPRM1 gene.
(The numbers in the squares are D’X 100. Squares are colored bright red if the D’value is high (i.e. LD is strong) and the confidence in the value
of D’is high as well).
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Limited sample size, etiological heterogeneity and cli-
nical heterogeneity may result in inconsistent results
showing different associations between the OPRM1 gene
and SZ [18,33,51], and therefore, the conclusion of this
study may be viewed in this context. Further investiga-
tions using larger sample sizes and family-based studiesTable 5 Comparison of haplotype frequencies for four OPRM1
Haplotypes
rs1799971 rs2075572 rs648893 rs671531 Case
A C C A 78.74
A C C G 14.23
A C T A 127.67
A G C A 1.48(
A G C G 46.88
G C C A 22.97
G C C G 68.80
G C T A 67.55
G G C A 21.59
G G C G 72.30
G C T G 0.04(
G G T G 5.75(will undoubtedly add further valuable insight into the
implications of the relationship between OPRM1 gene
polymorphisms and SZ.
Conclusion
In conclusion, the present study suggests that OPRM1
gene polymorphisms may be associated with SZ risk inpolymorphisms between SZ cases and controls
(freq) Control (freq) Odds Ratio (95% CI) P value*
(0.149) 71.94(0.136) 1.119(0.791-1.583) 0.53
(0.027) 82.39(0.156) 0.149(0.084-0.266) <0.01
(0.242) 126.27(0.239) 1.022(0.769-1.358) 0.88
0.003) 24.66(0.047) - -
(0.089) 60.74(0.115) 0.753(0.503-1126) 0.17
(0.044) 55.75(0.106) 0.386(0.233-0.638) <0.01
(0.130) 17.92(0.034) 4.317(2.526-7.377) <0.01
(0.128) 59.73(0.113) 1.158(0.798-1.681) 0.44
(0.041) 1.65(0.003) - -
(0.137) 26.95(0.051) 2.984(1.881-4.732) <0.01
0.000) 0.00(0.000) - -
0.011) 0.00(0.000) - -
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http://www.biomedcentral.com/1471-244X/13/107the southern Chinese Han population, and G alleles of
rs1799971 and rs2075572 are protective factors in male
and female SZ patients respectively, and these associa-
tions may largely depend on population characteristics
and geographic location.
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